|
Demographic and general characteristics
|
|
Male gendera
|
26 (74%)
|
12 (57%)a
|
14 (100%)a
|
|
Age (years, median, Q1-Q3)
|
48 (44–54)
|
48 (43–54)
|
49 (44–54)
|
|
Caucasian race
|
35 (100%)
|
21 (100%)
|
14 (100%)
|
|
BMI (Kg/m2)
|
25.6 (22.2-27.2)
|
25.3 (21.6-27.5)
|
25.8 (24.1-26.9)
|
|
Risk Group
|
|
Ex-intravenous drug users
|
8 (23%)
|
7 (33%)
|
1 (7%)
|
|
Men-having-sex-with-men
|
21 (57%)
|
7 (33%)
|
13 (93%)
|
|
Heterosexual infection
|
6 (17%)
|
6 (29%)
|
0
|
|
Vertical infection
|
1 (3%)
|
1 (5%)
|
0
|
|
HIV infection variables
|
|
Previous AIDS-defining events
|
9 (25%)
|
7 (33%)
|
2 (14%)
|
|
Nadir CD4+ T-cells/μL (median, Q1-Q3)
|
94 (37–197)
|
80 (34–140)
|
188 (77–258)
|
|
Current CD4+ T-cells/μL (median, Q1-Q3)
|
577 (406–726)
|
485 (374–686)
|
624 (527–740)
|
|
VL < 40 c/mL
|
34 (97%)
|
21 (100%)
|
13 (93%)
|
|
Hepatitis C virus coinfection
|
4 (11%)
|
4 (19%)
|
0
|
|
VACS Index
|
12 (5–19)
|
16 (6–24)
|
9 (0–12)
|
|
Smoking and Treatments
|
|
Smokers
|
8 (23%)
|
6 (29%)
|
2 (14%)
|
|
2NRTI + Protease inhibitor
|
14 (40%)
|
7 (33%)
|
7 (50%)
|
|
2NRTI + NNRTI
|
11 (31%)
|
7 (33%)
|
4 (29%)
|
|
Other ART regimens
|
10 (28%)
|
7 (33%)
|
3 (21%)
|
|
Beta blockersb
|
6 (17%)
|
5 (24%)
|
1 (7%)
|
|
Other anti-hypertensive drugsb
|
5 (14%)
|
2 (10%)
|
3 (21%)
|
|
Statinsb
|
10 (29%)
|
4 (19%)
|
6 (42%)
|
|
Fibratesb
|
2 (6%)
|
0
|
2 (14%)
|
|
Inclusion Criteria
|
|
Lipodystrophy
|
35 (100%)
|
21 (100%)
|
14 (100%)
|
|
≥ 1 metabolic syndrome criterion
|
32 (91%)
|
19 (90%)
|
13 (93%)
|
|
Blood triglycerides ≥150 mg/dL
|
14 (40%)
|
8 (38%)
|
6 (42%)
|
|
Blood HDL-C ≤40 (m) or ≤50 (w) mg/dL
|
12 (34%)
|
9 (43%)
|
3 (21%)
|
|
Blood glucose ≥110 mg/dL
|
1 (3%)
|
0
|
1 (7%)
|
|
Waist ≥102 (m) or ≥88 (w) cm
|
10 (28%)
|
8 (38%)
|
2 (14%)
|
|
SBP ≥150 or DBP ≥85 mmHg
|
12 (34%)
|
7 (33%)
|
5 (36%)
|
